Therefore, FLBZ may offer therapeutic benefits for dry age-related macular degeneration, promoting autophagy without the adverse effects associated with chronic mTOR inhibition (e.g., hyperlipidemia, insulin resistance, muscle wasting, etc.), and this could potentially be applied to AD protection [57]. This evidence concerns the gene MTOR and Alzheimer disease.